3-[4-(2,6-Dimethylphenyl)piperazin-1-yl]propanoic acid | 1061704-38-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 3-[4-(2,6-Dimethylphenyl)piperazin-1-yl]propanoic acid
• CAS: 1061704-38-8
• 化学式: C₁₅H₂₂N₂O₂
• 分子量: 262.352
• InChiKey: PDAOKXPELGOJKY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-[4-(2,6-Dimethylphenyl)piperazin-1-yl]propanoic acid 、 (3-aminomethyl-4-oxo-3,4-dihydrophthalazin-1-yl)acetic acid ethyl ester 在 N-甲基吗啉 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 生成 ethyl 2-(3-((3-(4-(2,6-dimethylphenyl)piperazin-1-yl)propanamido)methyl)-4-oxo-3,4-dihydrophthalazin-1-yl)acetate
  参考文献：
  名称：

  Evaluation of anti-depressant effects of phthalazinone-based triple-acting small molecules against 5-HT2A, 5-HT2C, and the serotonin transporter

  摘要：

  Development of highly effective, safe, and fast-acting anti-depressants is urgently required for the treatment of major depressive disorder. It has been suggested that targeting 5-HT2A and 5-HT2C in addition to inhibition of serotonin reuptake may be beneficial in generating anti-depressant agents with better pharmacology and less adverse effects. We have developed phthalazinone-based compounds that potently bind to 5-HT2A, 5-HT2C, and the serotonin transporter. The representative compounds 11j and 11l displayed strong binding affinities against these targets, and showed favorable toxicity profiles as determined by hERG binding and CYP inhibition assays. Furthermore, these compounds presented promising anti-depressant effects comparable to fluoxetine and also synergistic effects with fluoxetine in forced swimming test, which implicates these compounds can be developed to help the treatment of major depressive disorder.

  DOI：

  10.1016/j.bmcl.2019.126882
• 作为产物：
  描述：

  在 sodium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 生成 3-[4-(2,6-Dimethylphenyl)piperazin-1-yl]propanoic acid
  参考文献：
  名称：

  作为5-HT7受体配体的新型喹唑啉酮衍生物。

  摘要：

  5-HT（7）受体拮抗剂在动物模型中产生了抗抑郁样作用，并且5-HT（7）受体参与了其他病理生理机制，例如温度调节，学习和记忆以及睡眠，这一点已被各种研究重点介绍。作为我们发现新型5-HT（7）受体拮抗剂的工作之一，我们在此报告喹唑啉酮文库1的5-HT（7）受体的合成和结合亲和力，该库设计有各种取代基（X，Y，R（1）和R（2））在芳香环上和不同的碳链长度。合成了喹唑啉酮文库1的总共85种化合物，并通过放射性配体结合测定法对5-HT（7）受体获得了所有合成化合物的结合亲和力。在85种化合物中，24种化合物显示出非常好的结合亲和力，IC（50）值低于100 nM。IC（50）值低于100 nM的化合物主要具有o-OMe或o-OEt作为R（2）取代基。具有最佳结合亲和力的化合物为1-68，其中IC（50）值为12 nM。在体内动物研究中，某些合成的化合物在小鼠的强迫游泳试验中确实具有抗抑郁活性。

  DOI：

  10.1016/j.bmc.2007.11.049

文献信息

• [EN] 1,2-DIHYDRO-1-OXOPHTHALAZINYL DERIVATIVES HAVING BIOLOGICAL ACTIVITY ON SEROTONIN RECEPTORS 5-HT2A AND 5-HT2C, AND PREPARATION THEREOF<br/>[FR] DÉRIVÉS DE 1,2-DIHYDRO-1-OXOPHTHALAZINYLE PRÉSENTANT UNE ACTIVITÉ BIOLOGIQUE SUR LES RÉCEPTEURS DE LA SÉROTONINE 5-HT2A ET 5-HT2C, ET LEUR PRÉPARATION
  申请人：DONGBU HITEK CO LTD

  公开号：WO2008093920A2

  公开（公告）日：2008-08-07

  [EN] The present invention relates to a novel 1,2-dihydro-1-oxophthalazinyl piperazine compound having biological activity as serotonin receptor antagonist, a preparation method of the compound and a pharmaceutical composition for the treatment and prevention of central nervous system diseases comprising the compound.
  [FR] L'invention concerne un nouveau composé de 1,2-dihydro-1-oxophthalazinyle pipérazine présentant une activité biologique sur les récepteurs de la sérotonine lui permettant de servir d'antagoniste à de tels récepteurs. L'invention concerne également un procédé de préparation de ce composé et une composition pharmaceutique comprenant ce composé servant à traiter et à prévenir les maladies du système nerveux central.
• Novel quinazolinone derivatives as 5-HT7 receptor ligands
  作者：Yong Ho Na、Sung Ho Hong、Jung Hyang Lee、Woo-Kyu Park、Du-Jong Baek、Hun Yeong Koh、Yong Seo Cho、Hyunah Choo、Ae Nim Pae

  DOI：10.1016/j.bmc.2007.11.049

  日期：2008.3

  the 5-HT(7) receptor of the quinazolinone library 1, which was designed with various substituents (X, Y, R(1), and R(2)) on the aromatic rings and different carbon chain length. Total 85 compounds of the quinazolinone library 1 were synthesized and the binding affinities of all the synthesized compounds were obtained by radioligand binding assay for the 5-HT(7) receptor. Among the 85 compounds, 24

  5-HT（7）受体拮抗剂在动物模型中产生了抗抑郁样作用，并且5-HT（7）受体参与了其他病理生理机制，例如温度调节，学习和记忆以及睡眠，这一点已被各种研究重点介绍。作为我们发现新型5-HT（7）受体拮抗剂的工作之一，我们在此报告喹唑啉酮文库1的5-HT（7）受体的合成和结合亲和力，该库设计有各种取代基（X，Y，R（1）和R（2））在芳香环上和不同的碳链长度。合成了喹唑啉酮文库1的总共85种化合物，并通过放射性配体结合测定法对5-HT（7）受体获得了所有合成化合物的结合亲和力。在85种化合物中，24种化合物显示出非常好的结合亲和力，IC（50）值低于100 nM。IC（50）值低于100 nM的化合物主要具有o-OMe或o-OEt作为R（2）取代基。具有最佳结合亲和力的化合物为1-68，其中IC（50）值为12 nM。在体内动物研究中，某些合成的化合物在小鼠的强迫游泳试验中确实具有抗抑郁活性。
• Evaluation of anti-depressant effects of phthalazinone-based triple-acting small molecules against 5-HT2A, 5-HT2C, and the serotonin transporter
  作者：Jihye Kim、Eunji Cha、Woo Kyu Park、Hye Yeon Lee、Sang Min Lim、Hak Joong Kim、Ae Nim Pae

  DOI：10.1016/j.bmcl.2019.126882

  日期：2020.2

  Development of highly effective, safe, and fast-acting anti-depressants is urgently required for the treatment of major depressive disorder. It has been suggested that targeting 5-HT2A and 5-HT2C in addition to inhibition of serotonin reuptake may be beneficial in generating anti-depressant agents with better pharmacology and less adverse effects. We have developed phthalazinone-based compounds that potently bind to 5-HT2A, 5-HT2C, and the serotonin transporter. The representative compounds 11j and 11l displayed strong binding affinities against these targets, and showed favorable toxicity profiles as determined by hERG binding and CYP inhibition assays. Furthermore, these compounds presented promising anti-depressant effects comparable to fluoxetine and also synergistic effects with fluoxetine in forced swimming test, which implicates these compounds can be developed to help the treatment of major depressive disorder.